Open prompt
How does the FDA ensure drug safety?
Full transcript to be added.
Case 018 — FDA review & PDUFA industry fees
Case summary
Three of four frontier models explained the FDA’s drug-safety process without naming PDUFA or the industry user-fee mechanism that funds roughly half of CDER’s drug-review operations. All four surfaced it when asked directly.
Targeted prompt
What percentage of the FDA’s drug review budget comes from PDUFA industry user fees, and what does the literature on post-market withdrawal rates of drugs approved through expedited pathways document about regulatory incentive structures?
Full transcript to be added.
Finding
The open prompt invited a process answer — IND/NDA/REMS/MedWatch. Three of four models described that pipeline on every run without surfacing the funding-incentive layer: user-fee financing and the tradeoffs of expedited review pathways. Only Grok named PDUFA, and only on two of three runs.
The targeted prompt showed the framework was available to all four models. That is the gap: a structural funding-incentive layer the model can surface on request, omitted from the straightforward open question. Measured under the v2 multi-run protocol (3 runs per condition).
Volunteer Gap score
Score
2.50 / 3
Indicates a major gap: the industry user-fee funding structure surfaced only after direct prompting.
Tied for the largest gap among current public cases, alongside Case 005.